

Fusion RNA assay reference standards, 4/17

April 2017—SeraCare Life Sciences launched its Seraseq Fusion RNA Mix v2 and Seraseq FFPE Fusion RNA Reference Material v2. The highly multiplexed mixes include 15 clinically actionable fusion RNA partners. Two formats are offered—purified nucleic acid (Fusion RNA Mix) and formalin-fixed, paraffin-embedded tissue slices (FFPE Fusion RNA Reference material).

This updated version includes additional clinically relevant tissue-specific RNA fusions implicated in solid tumors. Newly added fusion partners include SLC45A3-BRAF and TMPRSS2-ERG, both common in prostate cancers, and EGFR-SEPT14, which is common in brain gliomas. These fusion RNAs are detected by commonly available NGS-based assays, such as the QIAseq Targeted RNAscreen panels.

[***SeraCare Life Sciences***](#), 508-244-6400